What is the Study about?

This is a follow-up to the PERL Study to investigate the long-term effects of 3-year allopurinol treatment on kidney function in people with type 1 diabetes and mild to moderate diabetic kidney disease. In the PERL study, participants received either allopurinol or a placebo for 3 years to determine whether allopurinol can reduce loss of renal function in people with type 1 diabetes.

What is involved in the Study?

Participants enrolled in the PERL study will return to the University of Minnesota for yearly visits. At these visits medical history will be reviewed, an electrocardiogram (ECG) taken, a kidney function test conducted, and digital eye photographs taken to assess for diabetic eye disease (diabetic retinopathy). Phone visits will occur every 3-6 months to determine current health and medications.

Principal Investigator

Luiza Caramori, MD, PhD, MSc

For More Information

Birgit Fink
(612) 301-2103